Regeneron Pharmaceuticals, Inc.
Every calculator, already run for REGN
Open the full toolkit →You have the numbers on REGN. Get the argument.
A written report on which of these readings actually decide the outcome for Regeneron Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
27 analysts covering REGNAnalyst Price Target Disagreement for Regeneron Pharmaceuticals, Inc.
Wall Street's bull case implies +31% from the current price; the bear case implies -7%. A 38% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for REGN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent inje…
REGN — frequently asked
Is REGN a buy right now?
Wall Street's consensus rating on Regeneron Pharmaceuticals, Inc. is Buy across 27 analysts, with a mean price target of $850.88 (+8% vs. the current $788.04). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is REGN overvalued?
REGN trades at 19.5x trailing earnings, against a DCF fair value of $1177 per share. The current price implies 1% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is REGN's next earnings date?
Regeneron Pharmaceuticals, Inc. is next scheduled to report earnings around Oct 30, 2026. A full REGN research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Regeneron Pharmaceuticals, Inc.?
Analysts covering Regeneron Pharmaceuticals, Inc. (REGN) range from a bear-case target of $730.00 to a bull-case high of $1,030.00, with a mean consensus target of $850.88 across 26 analysts. The spread of $300.00 (38% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Regeneron Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Regeneron Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full REGN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Regeneron Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.